Mesa Laboratories, Inc. cash flow to debt ratio of 25.37% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Mesa Laboratories, Inc.'s free cash flow has decreased 6.45% from $42.31M last year to $39.58M, signaling decreasing performance

Mesa Laboratories, Inc.'s debt to equity ratio is 0.52, which means that the company's assets are healthy financed, signaling financial stability.

Mesa Laboratories, Inc.'s debt has decreased relative to shareholder equity from 1.14 last year to 0.52 today, signaling strengthened financials

Mesa Laboratories, Inc. has a net debt to EBITDA ratio of 4.02x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Mesa Laboratories, Inc.'s interest coverage ratio of 2.07 indicates that earnings with margin can cover interest payments on company debt

Mesa Laboratories, Inc.'s profit margin has increased (-334.64%) in the last year from -0.82% to 1.92%, signaling increasing performance

Mesa Laboratories, Inc.'s short-term assets of $106.27M exceed its short-term liabilities of $61.90M

Mesa Laboratories, Inc.'s return on assets of 1.14% is lower than the 5.00% threshold, indicating inefficient asset utilization

Mesa Laboratories, Inc.'s return on equity of 2.59%, is lower than 15.00%, indicating bad performance

Mesa Laboratories, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Mesa Laboratories, Inc. had positive net income in 3 out of 5 years, indicating stable and consistent earnings

Mesa Laboratories, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Mesa Laboratories, Inc. has a free cash flow yield of 6.96%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Mesa Laboratories, Inc.'s yearly earnings has increased -440.02% since last year from $-1.97M to $6.71M, signaling increasing performance

Mesa Laboratories, Inc.'s yearly revenue has increased 3.38% since last year from $240.98M to $249.13M, signaling increasing performance

ROIC 3.14% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Mesa Laboratories, Inc.'s 3-year revenue CAGR of 4.38% is positive, indicating growing revenue over the past 3 years

Mesa Laboratories, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Mesa Laboratories, Inc. had positive ROE in 3 out of 5 years, indicating consistent and reliable returns on equity

Mesa Laboratories, Inc. is undervalued relative to its fair value price of 108.03 based on Discounted Cash Flow model

Mesa Laboratories, Inc. has an earnings yield of 0.83%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Mesa Laboratories, Inc. is overvalued relative to its fair value price of 25.76 based on EBITDA multiple model

Mesa Laboratories, Inc. has an EV/EBITDA ratio of 20.14x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Mesa Laboratories, Inc. is overvalued relative to its fair value price of 18.90 based on Earnings Fair Value model

Mesa Laboratories, Inc. has a PEG-ratio over 1 which is considered overvalued

Mesa Laboratories, Inc. has a price-to-book ratio of 3.05x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Mesa Laboratories, Inc. has a price-to-sales ratio of 2.30x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue